Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Coppo

Showing results (131-140 of 199) with videos related to

Pageof 20
Sort By:
Haematologica|November 20, 2025
Novel cryptic ADAMTS13 epitopes uncover a distinct open ADAMTS13 conformation in immune-mediated TTPQuintijn Bonnez, Febe Boudry, Laure De Waele, et al.
The New England Journal of Medicine|January 10, 2019
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic PurpuraMarie Scully, Spero R Cataland, Flora Peyvandi, et al.
Blood Advances|August 8, 2025
Trp1250, Lys1252 and Arg1367 of ADAMTS13 comprise a hot-spot for anti-CUB domain antibodies in patients with iTTPTim Postmus, Robin Jansen, Paul Kaijen, et al.
BMC Nephrology|July 21, 2021
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centreMaximilien Grall, Florence Daviet, Noémie Jourde Chiche, et al.
British Journal of Clinical Pharmacology|November 6, 2018
Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohortFlorence Daviet, Franck Rouby, Pascale Poullin, et al.
Leukemia & Lymphoma|October 4, 2017
Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort studyVincent Jachiet, Arsène Mekinian, Fabrice Carrat, et al.
Blood Advances|September 8, 2021
Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpuraKadri Kangro, Elien Roose, Bérangère S Joly, et al.
American Journal of Hematology|September 20, 2016
Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative studyYgal Benhamou, Gilles Paintaud, Elie Azoulay, et al.
Hemasphere|September 5, 2020
Understanding the Health Literacy in Patients With Thrombotic Thrombocytopenic PurpuraLeydi C Velasquez Pereira, Bogac Ercig, Kadri Kangro, et al.
Blood|May 30, 2014
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpuraMiguel Hie, Julie Gay, Lionel Galicier, et al.
Pageof 20

Showing results (131-140 of 199) with videos related to

Sort By:
Pageof 20
Haematologica|November 20, 2025
Novel cryptic ADAMTS13 epitopes uncover a distinct open ADAMTS13 conformation in immune-mediated TTPQuintijn Bonnez, Febe Boudry, Laure De Waele, et al.
The New England Journal of Medicine|January 10, 2019
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic PurpuraMarie Scully, Spero R Cataland, Flora Peyvandi, et al.
Blood Advances|August 8, 2025
Trp1250, Lys1252 and Arg1367 of ADAMTS13 comprise a hot-spot for anti-CUB domain antibodies in patients with iTTPTim Postmus, Robin Jansen, Paul Kaijen, et al.
BMC Nephrology|July 21, 2021
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centreMaximilien Grall, Florence Daviet, Noémie Jourde Chiche, et al.
British Journal of Clinical Pharmacology|November 6, 2018
Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohortFlorence Daviet, Franck Rouby, Pascale Poullin, et al.
Leukemia & Lymphoma|October 4, 2017
Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort studyVincent Jachiet, Arsène Mekinian, Fabrice Carrat, et al.
Blood Advances|September 8, 2021
Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpuraKadri Kangro, Elien Roose, Bérangère S Joly, et al.
American Journal of Hematology|September 20, 2016
Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative studyYgal Benhamou, Gilles Paintaud, Elie Azoulay, et al.
Hemasphere|September 5, 2020
Understanding the Health Literacy in Patients With Thrombotic Thrombocytopenic PurpuraLeydi C Velasquez Pereira, Bogac Ercig, Kadri Kangro, et al.
Blood|May 30, 2014
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpuraMiguel Hie, Julie Gay, Lionel Galicier, et al.
Pageof 20